4/A: AN2 Therapeutics Executive Joshua M. Eizen Reports Amended Vesting Schedule for Restricted Stock Units
Ownership Disclosure
Joshua M. Eizen, Chief Legal Officer of AN2 Therapeutics, reports an amendment to the vesting schedule of his restricted stock units.
Summary
- This is an amendment to a Form 4 filing by Joshua M. Eizen, Chief Legal Officer of AN2 Therapeutics, Inc.
- The amendment concerns the vesting schedule of restricted stock units.
- The original transaction date was March 15, 2024, and the original filing date was March 18, 2024.
- Eizen acquired 30,000 shares of common stock on March 15, 2024, at a price of $0.
- Following the reported transaction, Eizen beneficially owns 32,447 shares of common stock directly.
- The vesting schedule for the restricted stock units is 1/4th of the shares vesting annually over four years from January 1, 2024, subject to continuous service.
Sentiment
Score: 5
Explanation: This is a neutral filing regarding stock ownership and vesting, with no inherent positive or negative implications.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| January 1, 2024 | Vesting schedule begins with 1/4th of shares vesting annually over four years. |
| March 15, 2024 | Date of transaction where 30,000 shares of common stock were acquired. |
| March 18, 2024 | Date of original Form 4 filing. |
| March 29, 2024 | Date of amended filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.